Sign in Subscribe
Stock offerings

Ekso Bionics Holdings, Inc. Announces Public Offering of 6,000,000 Total Units and Pre-Funded Units

Strategic Insights

— 1 min read

Ekso Bionics Holdings, Inc., a leading company in exoskeleton technology for medical and industrial use, has announced the pricing of an underwritten public offering of 6,000,000 total units and pre-funded units for gross proceeds of approximately $6.0 million. The offering is comprised of 3,100,000 units priced at $1.00 per unit and 2,900,000 pre-funded units priced at $0.999 per unit. The securities are immediately separable and will be issued separately.

Key Takeaways:

  • The public offering is priced at $1.00 per unit for 3,100,000 units and $0.999 per unit for 2,900,000 pre-funded units, resulting in gross proceeds of approximately $6.0 million.
  • Each unit consists of one share of common stock, one Series A Warrant, and one Series B Warrant, while each pre-funded unit consists of one pre-funded warrant, one Series A Warrant, and one Series B Warrant.
  • The net proceeds from this offering will be used for general corporate purposes, which may include growth and expansion of the EksoHealth segment, research and development activities, selling, general and administrative costs, and pursuing strategic initiatives.
  • The Company intends to use the proceeds to pursue potential synergistic and accretive acquisitions and meet its working capital needs.
  • The closing of the offering is expected to take place on or about September 3, 2024, subject to customary closing conditions.

Statistics:

  • 6,000,000 total units and pre-funded units will be issued in the public offering.
  • The public offering is priced at $1.00 per unit for 3,100,000 units and $0.999 per unit for 2,900,000 pre-funded units, resulting in gross proceeds of approximately $6.0 million.
  • Each unit and pre-funded unit will include one share of common stock, and two warrants with different expiration dates (Series A Warrant and Series B Warrant).
  • The Company intends to use the net proceeds for various purposes, including growth and expansion of the EksoHealth segment.

Sources:

  • Ekso Bionics Holdings, Inc. press release, dated August [Undisclosed] 2024.

Read more